Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 1581 • ACR Convergence 2024
Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
shiri keret¹, Lisa Kaly², Georg Schett³, Christina Bergmann⁴, Joerg Henes⁵, Gleb Slobodin² and Doron Rimar², ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁵University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Baseline high Neutrophil- to- lymphocyte ratio (NLR) (higher than 2.95) is associated with severe progressive skin and lung disease and with reduced 5-year survival…
Abstract Number: 2396 • ACR Convergence 2024
PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
Anna Korogodina¹, Erin Sundel¹, Yaroslav Markov², Vasileios Kyttaris³, Julianne O'Connell¹ and Suzanne Krishfield¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Yale School of Medicine, New Haven, ³BIDMC, Boston, MA
Background/Purpose: SLE-related outcomes are traditionally assessed by clinician-derived measures. However, these assessments often do not fully capture how patients experience their disease. We assessed the alignment…
Abstract Number: 2509 • ACR Convergence 2024
Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency
Benjamin Turturice¹, Alice Fike¹, Bhavisha Patel², Emma Groarke², Karyssa Stonick¹, Shanni Liu¹, Wendy Goodspeed¹, Kaitlin Quinn¹, Neal Young² and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: VEXAS is a multisystem autoinflammatory disorder due to somatic mutations in UBA1. The disease is characterized by ineffective hematopoiesis with increased risk of transfusion…
Abstract Number: 0051 • ACR Convergence 2024
Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis
Arkaitz Mucientes¹, jose Manuel Lisbona-Montañez², Patricia Ruiz-Limón³, Sara Manrique-Arija⁴, Aimara García-Studer⁴, Fernando Ortiz-Márquez⁴, Natalia Mena Vázquez⁵ and Antonio Fernández-Nebro⁶, ¹IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, ²University of Malaga, Malaga, Andalucia, Spain, ³IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, ⁴Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁵IBIMA, Málaga, Andalucia, Spain, ⁶Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain
Background/Purpose: The etiology of Rheumatoid Arthritis (RA) is not fully understood. Recent studies point to intestinal permeability as an important factor in the establishment and…
Abstract Number: 0270 • ACR Convergence 2024
Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Muneet Gill, Hongshu Guan, Jamie Collins and Sara Tedeschi, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease is a crystalline arthritis affecting older adults. Systemic inflammation occurs during flares of acute calcium pyrophosphate (CPP) crystal arthritis…
Abstract Number: 0758 • ACR Convergence 2024
Difficult to Treat Takayasu Arteritis: Comparative Efficacy of Colchicine and Tofacitinib
Ravi Kumar¹, Prabhu Vasanth², Ramya Janardhana³, Arvind Ganapati⁴, Abhishek Patil⁵, Avinash Jain⁶, Benzeeta Pinto⁷, Ramesh Jois⁸, Shivraj Padiyar⁹, John Mathew⁹, Vineeta Shobha³, George Joseph² and Ruchika goel⁹, ¹Christian Medical college , Vellore , India, Bangalore, India, ²Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ³St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁴Kasturba Medical College, Rheumatology Division, Manipal , India, Vellore, Tamil Nadu, India, ⁵Manipal Hospital, Rheumatology, Bengaluru, India, Bengaluru, India, ⁶SMS Medical College and Hospital, Jaipur ,India, JAIPUR, India, ⁷St. John’s Medical College, Bengaluru , India, Bengaluru, India, ⁸Manipal Hospital ,Rheumatology, Millers Road, Bengaluru, India, Bengaluru, India, ⁹Christian Medical college , Vellore , India, Vellore, India
Background/Purpose: Biologic DMARDs (bDMARDs) are mainstay in management of patients with difficult to treat Takayasu Arteritis (D2TTAK). The cost of long-term biologics is prohibitory in…
Abstract Number: 0947 • ACR Convergence 2024
REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis
Alexandra Gardino¹, Neil Bifulco¹, Jeremy Hunt², Rishi Vaswani¹, Donglim Park², Patrick Metz², Ksenya Cohen-Katsenelson², Jeong-Ho Kim², Xia Tian², Aryan Alavi², Ajay Nirula², Daniel Treiber², Brian Hodous¹, Seong Kim³ and Paul Smith², ¹Recludix Pharma, Cambridge, MA, ²Recludix Pharma, San Diego, CA, ³Department of Microbiology and Immunology, LSU Health Shreveport, Shreveport, LA
Background/Purpose: Inhibition of JAK family signaling has translated into clinically meaningful efficacy in rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. However, small molecule JAK/TYK2…
Abstract Number: 1355 • ACR Convergence 2024
Genetically-determined Variation in C-reactive Protein Impacts Disease Activity Assessment in Rheumatoid Arthritis
Thomas Riley¹, Austin Wheeler², grant Cannon³, Sauer brian⁴, Gary Kunkel⁵, Katherine Wysham⁶, Bryant England², Kristin Wipfler⁷, Kaleb Michaud², Beth Wallace⁸, Rachel Elam⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Gail Kerr¹², Isaac Smith¹³, John Richards¹⁴, Iris Lee¹⁵, Michael March¹⁶, Scott Damrauer¹⁷, Anurag Verma¹⁷, Michael George¹⁷, Ted Mikuls² and Joshua Baker¹⁷, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁷FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Augusta University, Evans, GA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹³Duke University Hospital, Durham, NC, ¹⁴Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁵Washington University in St Louis, Saint Louis, MO, ¹⁶Children's Hospital of Philadelphia, Philadelphia, ¹⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: C-reactive protein (CRP) is often used as a biomarker for disease activity in patients with rheumatoid arthritis (RA). We evaluated whether rs1205, a common…
Abstract Number: 1475 • ACR Convergence 2024
Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial
Raj Sengupta¹, Pedro M Machado², Philippe Goupille³, Victoria Navarro Compán⁴, Huji Xu⁵, mohamed sheesh⁶, Khai Jing Ng⁷, Marcus Ngantcha⁸, Hagen Russ⁹, Gabriel Doridot⁶ and Xenofon Baraliakos¹⁰, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ³UPR CNRS 4301 CBM, NMNS, University of Tours; Department of Rheumatology, University hospital, Tours, Tours, France, ⁴La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁵Changzheng Hospital, Naval Medical University, Shanghai, China, Shanghai, China (People's Republic), ⁶Eli Lilly, Indianopolis, IN, ⁷Eli Lilly and Company, Madrid, Spain, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Eli Lilly, Indianopolis, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Elevated baseline (BL) C-reactive protein (CRP) level can serve as a predictor for treatment response to TNF inhibitors in patients (pts) with r-axSpA. The…
Abstract Number: 0484 • ACR Convergence 2023
Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study
Lihi Eder¹, Vinod Chandran², Cheryl Rosen³, Richard J. Cook⁴ and Dafna Gladman⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Dermatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Simple and accessible biomarkers that predict the development of psoriatic arthritis (PsA) among psoriasis patients are critically needed to improve early detection of high-risk…
Abstract Number: 0518 • ACR Convergence 2023
Tofacitinib Efficacy and Safety in Patients with Ankylosing Spondylitis by Baseline C-Reactive Protein Levels: A Post Hoc Analysis
Atul Deodhar¹, Xenofon Baraliakos², Marina Nighat Magrey³, Lianne Gensler⁴, Amit V. Thorat⁵, Surya Pemmaraju⁶, Mary Jane Cadatal⁷ and Peter Nash⁸, ¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Case Western Reserve University, University Hospitals, Cleveland, OH, ⁴University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵Pfizer Australia, Sydney, Australia, ⁶Pfizer Inc., Chennai, Tamil Nadu, India, ⁷Pfizer Inc., Manila, Philippines, ⁸School of Medicine, Griffith University, Brisbane, Australia
Background/Purpose: Elevated baseline (BL) CRP levels can predict treatment response in patients (pts) with AS. Tofacitinib is a Janus kinase inhibitor for the treatment of…
Abstract Number: 0522 • ACR Convergence 2023
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status
Xenofon Baraliakos¹, Désirée van der Heijde², Pedro Machado³, Victoria Navarro-Compán⁴, Lianne Gensler⁵, Patricia Pertel⁶, Erhard Quebe-Fehling⁶, Aimee Readie⁷, Hanno Richards⁶ and Denis Poddubnyy⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, Immunology, East Hanover, NJ, ⁸Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: SURPASS, a phase 3b randomized controlled study in patients with radiographic axial spondyloarthritis (r-axSpA), found low spinal radiographic progression over 2 years with no…
Abstract Number: 1842 • ACR Convergence 2023
Reduction in the Concomitant Ordering of Erythrocyte Sedimentation Rate and C-Reactive Protein Within the Rheumatology Clinics at an Academic Medical Center
Ruchi Desai¹, Nainesh Shah¹, Ray Zhang¹, Maria Bacalao², Haidy Galous³, David Karp¹ and Puneet Bajaj¹, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³UT Southwestern, Southlake, TX
Background/Purpose: ESR and CRP are two laboratory values usedto assess inflammation. There is data to support that CRPis superior to ESR to detect/monitor inflammation or…
Abstract Number: 2100 • ACR Convergence 2023
Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis
Jon Giles and Joan Bathon, Columbia University, New York, NY
Background/Purpose: C-reactive protein (CRP) is used as an indicator of disease activity in people with RA.However, adipose tissue also expresses inflammatory cytokines that induce hepatic…
Abstract Number: 0885 • ACR Convergence 2022
Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study
brittany weber¹, Dana Weisenfeld¹, Thany Seyok¹, Elena Massarotti¹, Selena Huang¹, Derrick Todd¹, Jonathan Coblyn¹, michael weinblatt¹, Tianrun Cai¹, Kumar Dahal¹, leanne BArrett¹, Daniel Solomon¹, Jorge Plutzky¹, Marcy Bolster², marcelo Dicarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased cardiovascular (CV) risk. Coronary flow reserve (CFR) is a quantitative imaging biomarker of CV risk that…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].